Cerwinka Franz
Known title: SVP and President, Emerging MaCIK: 0001813828
Associated companies
Transaction History
| XYL | ▲ Buy | Grant | 1,203 | $154K | 3/1/2024 | View on chart |
| XYL | ▲ Buy | Grant | 1,956 | $250K | 3/1/2024 | View on chart |
| XYL | ▼ Sell | Tax Withholding | 1,509 | $193K | 3/1/2024 | View on chart |
| XYL | ▼ Sell | Tax Withholding | 730 | $93K | 3/1/2024 | View on chart |
| XYL | ▼ Sell | Open Market | 1,341 | $171K | 3/1/2024 | View on chart |
| XYL | ▲ Buy | Grant | 1,563 | $200K | 3/1/2024 | View on chart |
| XYL | ▼ Sell | Open Market | 2,408 | $293K | 2/8/2024 | View on chart |
| XYL | ▼ Sell | Tax Withholding | 1,368 | $149K | 6/12/2023 | View on chart |
| XYL | ▼ Sell | Tax Withholding | 519 | $52K | 3/1/2023 | View on chart |
| XYL | ▲ Buy | Grant | 1,855 | $0 | 3/1/2023 | View on chart |
| XYL | ▲ Buy | Grant | 3,811 | $0 | 2/27/2023 | View on chart |
| XYL | ▼ Sell | Tax Withholding | 1,130 | $116K | 2/27/2023 | View on chart |
| XYL | ▼ Sell | Tax Withholding | 236 | $24K | 2/27/2023 | View on chart |
| XYL | ▼ Sell | Open Market | 925 | $70K | 6/14/2022 | View on chart |
| XYL | ▼ Sell | Open Market | 157 | $14K | 3/2/2022 | View on chart |
| XYL | ▼ Sell | Open Market | 292 | $25K | 3/1/2022 | View on chart |
| XYL | ▲ Buy | Grant | 1,873 | $0 | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Xylem sees broad analyst price target cuts
Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.
Xylem sees broad analyst price target cuts. Several major banks, including Mizuho, Oppenheimer, and Citigroup, recently lowered their price targets for Xylem. While most firms maintained positive ratings, the reduction in targets reflects a more conservative outlook on the stock's near-term value. The company also announced it will participate in upcoming investor conferences to discuss its strategy.